Product Description
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Belgium | Ireland | Taiwan | United Arab Emirates
Approved Indications: None
Known Adverse Events: None
Company: Collegium
Company Location: STOUGHTON MA 02072
Company CEO: Joseph Ciaffoni
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Poland
Active Clinical Trial Count: 1
Highest Development Phases
Phase 3: Atherosclerosis|Peripheral Arterial Disease
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
CADET-PAD | P3 |
Unknown Status |
Atherosclerosis|Peripheral Arterial Disease |
2026-02-03 |